Obesity alters pathology and treatment response in inflammatory disease

Decades of work have elucidated cytokine signalling and transcriptional pathways that control T cell differentiation and have led the way to targeted biologic therapies that are effective in a range of autoimmune, allergic and inflammatory diseases. Recent evidence indicates that obesity and metabolic disease can also influence the immune system(1-7), although the mechanisms and effects on immunotherapy outcomes remain largely unknown. Here, using two models of atopic dermatitis, we show that lean and obese mice mount markedly different immune responses. Obesity converted the classical type 2 T helper (T(H)2)-predominant disease associated with atopic dermatitis to a more severe disease with prominent T(H)17 inflammation. We also observed divergent responses to biologic therapies targeting T(H)2 cytokines, which robustly protected lean mice but exacerbated disease in obese mice. Single-cell RNA sequencing coupled with genome-wide binding analyses revealed decreased activity of nuclear receptor peroxisome proliferator-activated receptor-gamma (PPAR gamma) in T(H)2 cells from obese mice relative to lean mice. Conditional ablation of PPAR gamma in T cells revealed that PPAR gamma is required to focus the in vivo T-H response towards a T(H)2-predominant state and prevent aberrant non-T(H)2 inflammation. Treatment of obese mice with a small-molecule PPAR gamma agonist limited development of T(H)17 pathology and unlocked therapeutic responsiveness to targeted anti-T(H)2 biologic therapies. These studies reveal the effects of obesity on immunological disease and suggest a precision medicine approach to target the immune dysregulation caused by obesity.

Automated summary

Obesity can disrupt immune responses and alter the effectiveness of immunotherapies by changing T cell immune reactions and decreasing the activity of PPAR gamma in Th2 cells.